Analysts expect OraSure Technologies, Inc. (NASDAQ:OSUR) to announce $47.97 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for OraSure Technologies’ earnings. The lowest sales estimate is $45.50 million and the highest is $50.45 million. OraSure Technologies posted sales of $35.50 million in the same quarter last year, which suggests a positive year over year growth rate of 35.1%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, February 14th.

According to Zacks, analysts expect that OraSure Technologies will report full year sales of $47.97 million for the current year, with estimates ranging from $160.60 million to $165.48 million. For the next year, analysts expect that the firm will report sales of $175.78 million per share, with estimates ranging from $173.00 million to $178.55 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover OraSure Technologies.

OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.09. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The company had revenue of $42.30 million for the quarter, compared to the consensus estimate of $40.87 million. During the same quarter in the previous year, the company earned $0.11 EPS. OraSure Technologies’s quarterly revenue was up 31.0% compared to the same quarter last year.

A number of research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research report on Wednesday, September 20th. ValuEngine downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. Jefferies Group downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. BidaskClub upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Thursday, December 21st. Finally, Canaccord Genuity reiterated a “buy” rating and set a $22.00 target price on shares of OraSure Technologies in a research report on Tuesday, September 19th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $19.65.

In other OraSure Technologies news, Director Mara G. Aspinall acquired 5,000 shares of the stock in a transaction on Tuesday, November 7th. The shares were purchased at an average price of $14.23 per share, for a total transaction of $71,150.00. Following the completion of the acquisition, the director now owns 5,000 shares in the company, valued at approximately $71,150. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 6.40% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OSUR. Daruma Capital Management LLC raised its holdings in OraSure Technologies by 2,761.0% during the second quarter. Daruma Capital Management LLC now owns 2,821,506 shares of the medical instruments supplier’s stock worth $48,699,000 after buying an additional 2,722,886 shares during the last quarter. Vanguard Group Inc. raised its holdings in OraSure Technologies by 19.8% during the second quarter. Vanguard Group Inc. now owns 5,352,832 shares of the medical instruments supplier’s stock worth $92,390,000 after buying an additional 886,333 shares during the last quarter. Fuller & Thaler Asset Management Inc. raised its holdings in OraSure Technologies by 175.6% during the third quarter. Fuller & Thaler Asset Management Inc. now owns 898,397 shares of the medical instruments supplier’s stock worth $20,214,000 after buying an additional 572,397 shares during the last quarter. Robeco Institutional Asset Management B.V. raised its holdings in OraSure Technologies by 2,181.8% during the third quarter. Robeco Institutional Asset Management B.V. now owns 434,550 shares of the medical instruments supplier’s stock worth $9,778,000 after buying an additional 415,506 shares during the last quarter. Finally, SG Capital Management LLC acquired a new position in OraSure Technologies during the third quarter worth $9,205,000. Hedge funds and other institutional investors own 94.43% of the company’s stock.

OraSure Technologies (NASDAQ:OSUR) opened at $19.81 on Friday. OraSure Technologies has a 1 year low of $8.39 and a 1 year high of $23.01. The stock has a market cap of $1,197.80, a price-to-earnings ratio of 37.98, a P/E/G ratio of 4.43 and a beta of 1.27.

TRADEMARK VIOLATION WARNING: “$47.97 Million in Sales Expected for OraSure Technologies, Inc. (OSUR) This Quarter” was reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2018/01/14/47-97-million-in-sales-expected-for-orasure-technologies-inc-osur-this-quarter.html.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Get a free copy of the Zacks research report on OraSure Technologies (OSUR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.